XML 85 R25.htm IDEA: XBRL DOCUMENT v3.24.4
Share-based compensation (Notes)
12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Share-based compensation Stock award and incentive plan
For the purpose of attracting and retaining the highest-quality personnel, providing for additional incentives, and promoting the
success of our Company, we generally issue share-based compensation in the form of restricted stock, pursuant to our stock award and
incentive plan. We have not granted any options since 2002. Each restricted share issued reduced our share reserve by one share (1:1
ratio). As of December 31, 2024, there were 4,665,494 shares reserved for the granting of future stock-based awards under our stock
award and incentive plan.
In addition, our stock award and incentive plan permits us to issue share awards to our employees, non-employees, and non-
employee directors. A share award is an award of common stock that (i) may be fully vested upon issuance or (ii) may be subject to the
risk of forfeiture under Section 83 of the Code. Shares issued generally vest over a four-year period from the date of issuance, and the
sale of the shares is restricted prior to the date of vesting. Certain restricted share awards are also subject to an additional one-year
holding period after vesting. The unearned portion of time-based share awards is amortized as share-based compensation expense on
a straight-line basis over the vesting period. Certain restricted share awards are subject to vesting based upon the satisfaction of levels
of performance or market conditions. Failure to satisfy the threshold performance conditions will result in the forfeiture of shares and in
a reversal of previously recognized share-based compensation expense. Failure to satisfy the market condition results in the forfeiture
of shares but does not result in a reversal of previously recognized share-based compensation expense, provided that the requisite
service has been rendered. Forfeiture of time-based, performance-based, or market-based awards due to the failure to meet the service
requirement results in the reversal of previously recognized share-based compensation expense.
The following is a summary of the stock awards activity under our equity incentive plan and related information for the years
ended December 31, 2024, 2023, and 2022 (dollars in thousands, except per share information):
Number of Share
Awards
Weighted-Average
Grant Date
Fair Value per Share
Outstanding at December 31, 2021
1,823,460
$
150.89
Granted
1,032,731
$
141.58
Vested
(749,101)
$
146.25
Forfeited
(19,569)
$
160.83
Outstanding at December 31, 2022
2,087,521
$
149.96
Granted
1,522,058
$
108.22
Vested
(798,729)
$
149.41
Forfeited
(56,689)
$
104.65
Outstanding at December 31, 2023
2,754,161
$
127.34
Granted
615,192
$
102.96
Vested
(951,195)
$
136.09
Forfeited
(180,253)
$
109.63
Outstanding at December 31, 2024
2,237,905
$
118.34
Year Ended December 31,
2024
2023
2022
Total grant date fair value of stock awards vested
$129,449
$119,335
$109,557
Total gross compensation recognized for stock awards
$118,439
$139,675
$104,424
Capitalized stock compensation
$58,805
$56,817
$46,684
Certain restricted stock awards granted during 2024, 2023, and 2022 are subject to performance and market conditions. The
grant date fair value of these awards is determined using a Monte Carlo simulation pricing model using the following assumptions for
2024, 2023, and 2022, respectively: (i) expected term of 3.0 years, 3.0 years, and 2.8 years (equal to the remaining performance
measurement period at the grant date), (ii) volatility of 28.7%, 32.0%, and 30.0% (approximating a blended average of implied and
historical volatilities), (iii) dividend yield of 3.3%, 2.8%, and 2.5%, and (iv) risk-free rate of 4.18%, 4.22%, and 2.47%.
As of December 31, 2024, there was $177.2 million of unrecognized compensation related to unvested share awards under
the equity incentive plan, which is expected to be recognized over the next four years and has a weighted-average vesting period of
approximately 20 months.